Blog
RSS FeedPosted by Michael Wonder on 01 Aug 2025
Serplulimab in combination with carboplatin and etoposide phosphate for the first-line treatment of patients with extensive-stage small-cell lung cancer
30 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Aug 2025
BeOne Medicines receives PRIME designation from the EMA for BGB-16673 in Waldenström’s macroglobulinaemia
31 July 2025 - Decision highlights the promise of BGB-16673, an investigational and potentially first in class BTK degrader designed ...
Posted by Michael Wonder on 01 Aug 2025
Reimbursement for oral Fabry disease drug Galafold expanded to first-line treatment
1 August 2025 - Handok's Fabry disease treatment, Galafold (migalastat), will have its insurance coverage criteria expanded to include first-line ...
Posted by Michael Wonder on 01 Aug 2025
Lenz Therapeutics announces US FDA approval of Vizz for the treatment of presbyopia
31 July 2025 - Vizz samples and product availability in the US expected as early as October 2025. ...
Posted by Michael Wonder on 01 Aug 2025
Norgine welcomes PBS listing in Australia of Ifinwil (eflornithine) for patients with high-risk neuroblastoma
1 August 2025 - Approximately 50 children in Australia are diagnosed with neuroblastoma each year, with nearly half classified as having ...
Posted by Michael Wonder on 01 Aug 2025
Trump takes aim at ‘foreign freeloading nations’ over drug prices in new threat to PBS
1 August 2025 - US President Donald Trump has blamed “foreign freeloading nations” for the high drug prices faced by ...
Posted by Michael Wonder on 01 Aug 2025
Novartis twice yearly Leqvio (inclisiran) receives FDA approval for new indication enabling first-line use
31 July 2025 - 4 out of 5 atherosclerotic cardiovascular disease patients do not reach guideline-recommended LDL-C target, reinforcing urgent need ...
Posted by Michael Wonder on 01 Aug 2025
ICER to assess therapies for IgA nephropathy
31 July 2025 - Report will be subject of CTAF meeting in February 2026; draft scoping document open to public ...
Posted by Michael Wonder on 01 Aug 2025
US FDA approves new Biktarvy indication for people with HIV who are treatment experienced and restarting antiretroviral treatment
30 July 2025 - Gilead Sciences today announced that the US FDA has granted a new approval for a novel ...
Posted by Michael Wonder on 01 Aug 2025
Dostarlimab in combination with platinum-based chemotherapy for the treatment of patients with advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency
30 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 31 Jul 2025
Schedule of Pharmaceutical Benefits - 1 August 2015
1 August 2025 - The August 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Jul 2025
Revalesio receives FDA fast track designation for RNS60 for the treatment of acute ischaemic stroke
31 July 2025 - Revalesio today announced that the US FDA has granted fast track designation to RNS60, its lead investigational ...
Posted by Michael Wonder on 31 Jul 2025
New Zealand Pharmaceutical Schedule - 1 August 2025
1 August 2025 - - The August 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in ...
Posted by Michael Wonder on 31 Jul 2025
Glofitamab in combination with gemcitabine hydrochloride and oxaliplatin for the treatment of patients with relapsed or refractory diffuse large Bcell lymphoma
29 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Jul 2025
Health Canada expands approval of Scemblix, making it an option for newly diagnosed and previously treated chronic myeloid leukaemia patients
30 July 2025 - Scemblix is first to show superior efficacy and a favourable safety and tolerability profile in a Phase ...